<ul>
<li><strong>新的研究显示，29-42 岁的人群比其他年龄组更可能错过宫颈筛查。1</strong></li>
<li><strong>几乎三分之一的受访欧洲千禧一代符合常规宫颈筛查资格的人推迟或跳过了他们的预约。1</strong></li>
<li><strong>宫颈癌是最可预防的癌症之一，几乎所有病例都可以通过疫苗接种和定期筛查来避免。2</strong></li>
</ul>
<p>, /PRNewswire/ -- 罗氏（SIX: RO, ROG; OTCQX: RHHBY）今天宣布研究结果显示，31% 的符合条件的千禧一代推迟或错过了他们的宫颈筛查预约，比所有年龄组的平均水平高出 27%。这些发现来自于罗氏委托并由 GWI 在六个欧洲国家进行的对 5,518 名 16-64 岁互联网用户的调查。1</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg"/></p>
<p>尽管在许多国家筛查服务广泛免费或大幅补贴，但对于受访的千禧一代而言，特定的挑战使得获取常规宫颈筛查变得困难。除了对疼痛、尴尬或与筛查相关的污名的恐惧外，研究还揭示，千禧一代在平衡职业、照顾责任和人际关系方面面临特别的挑战。这些重叠的承诺似乎将宫颈筛查推到了他们优先事项的底部，导致错过或延迟预约的比例高于其他群体。</p>
<p>&#34;千禧一代常被称为 ‘拥有一切的世代’，在职业、照顾和社会期望之间忙碌。然而，他们往往把自己放在最后，&#34;罗氏诊断的健康政策与外部事务副总裁 Joanna Sickler 表示。&#34;研究显示，千禧一代在优先考虑宫颈筛查方面明显不足，原因是情感、后勤和社会压力的混合。设计像自我采样这样的解决方案，使筛查能够融入他们的现实中至关重要。这不仅重要，更是拯救生命的必要。&#34;</p>
<p>这些发现突显了针对千禧一代面临的障碍的实用、量身定制的干预措施的重要性。评论结果时，卡迪夫大学的 Daniel Kelly OBE 教授及欧洲癌症组织 HPV 和乙型肝炎行动网络的共同主席表示：&#34;医疗系统必须发展，以适应女性的生活方式，提供灵活、以人为本的筛查选项和疫苗接种机会，同时促进开放对话和社区参与，使宫颈健康成为共同责任。&#34;</p>
<p>恐惧仍然是宫颈筛查出席的最大障碍。30% 的女性将恐惧视为错过或延迟预约的主要原因，主要是由于对不适、疼痛或潜在结果的焦虑。调查还发现，职业承诺和工作场所的要求是一个主要因素，也是所有参与者的第二大障碍。高收入者（市场中收入范围的前 1/3）比平均水平更可能推迟预约，27% 的这一群体将工作场所的要求作为推迟的原因。推迟或取消筛查预约的千禧一代比普通人群更可能（20%）表示，工作场所的灵活性和鼓励会帮助他们优先考虑宫颈筛查。</p>
<p>照顾责任增加了复杂性，尤其是对于父母而言。对于许多人来说，家庭生活的需求优先于个人健康，27% 的受访父母表示他们推迟或取消了宫颈筛查预约。</p>
<p>这些挑战因缺乏对宫颈筛查的认识和讨论而加剧，调查中有一半女性认为没有支持或补贴医疗预约的计划。此外，近 50% 的受访者，包括 43% 的千禧一代，承认他们从未与任何人谈论过宫颈筛查，突显出一种普遍的文化不适，使许多人缺乏优先考虑筛查所需的情感支持或鼓励。</p>
<p>实用和情感支持是提高出席率的关键。在推迟筛查的千禧一代中，12% 的人认为旅行或儿童照顾的帮助是一个重要的动机，而 19% 的人表示，工作场所的更大灵活性和雇主的鼓励将帮助他们优先考虑预约。情感支持也起着作用，10% 的人表示，如果得到家人、朋友或同事的鼓励，他们更可能参加。</p>
<p><strong>宫颈癌：只有我们所有人才能结束</strong></p>
<p>每年，宫颈癌在全球影响超过 60 万名女性，2 然而几乎所有病例都可以通过疫苗接种、早期检测和前癌症的治疗来预防。2 在罗氏诊断，我们致力于通过集体行动消除宫颈癌。我们的活动 “宫颈癌：只有我们所有人才能结束” 专注于减少获取障碍，正常化关于宫颈健康的对话，并使更多符合条件的人能够参加常规筛查。</p>
<p>罗氏正在与医疗系统、政府和社区合作，提供灵活的筛查选项，如自我采样、包容性教育和关于早期检测重要性的清晰沟通。我们可以共同帮助提高出席率，赋予个人采取行动保护健康的能力，并防止宫颈癌夺去更多生命。消除宫颈癌始于我们所有人。</p>
<p>欲了解更多信息，请访问：https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
<p><strong>关于罗氏</strong> 罗氏成立于 1896 年，总部位于瑞士巴塞尔，是最早的工业品牌药物制造商之一，现已发展成为全球最大的生物技术公司和体外诊断领域的全球领导者。公司追求科学卓越，致力于发现和开发改善和拯救全球人民生命的药物和诊断工具。我们是个性化医疗的先驱，旨在进一步改变医疗服务的交付方式，以产生更大的影响。为了为每个人提供最佳护理，我们与许多利益相关者合作，将我们的诊断和制药优势与临床实践中的数据洞察相结合。</p>
<p>罗氏在追求长期视角的努力得到了认可，连续第十五年被道琼斯可持续发展指数评选为制药行业最可持续的公司之一。这一荣誉也反映了我们与每个国家的地方合作伙伴共同改善医疗服务可及性的努力。</p>
<p>美国的基因泰克是罗氏集团的全资成员。罗氏是日本中外制药的主要股东。</p>
<p>欲了解更多信息，请访问 www.roche.com。</p>
<p>本发布中使用或提及的所有商标均受法律保护。</p>
<p>[1] GWI – 罗氏。2025 年宫颈癌欧洲研究。</p>
<p>[2] 世界卫生组织。宫颈癌事实表。可在以下网址获取：https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
<p>[3] 疾病控制与预防中心，HPV 引起的癌症。可在以下网址获取：https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
<p><strong>罗氏诊断传播</strong></p>
<p><strong>凯瑟琳·阿格尔</strong> 罗氏诊断高级传播业务合作伙伴</p>
<p>kathryn.ager@roche.com</p>
<p>电话：+44 07745 115046</p>
<p>来源：罗氏</p>

罗氏(ADR)

<p>一项由罗氏委托的调查显示，31% 的 29 至 42 岁的欧洲千禧一代推迟或错过了宫颈癌筛查，这一比例显著高于其他年龄组。导致这一趋势的因素包括对疼痛和尴尬的恐惧，以及在工作和照顾责任之间平衡的挑战。调查结果强调了需要量身定制的干预措施，例如自我采样选项，以提高筛查出席率。罗氏旨在通过集体行动和提高对定期筛查重要性的认识来消除宫颈癌</p>

<ul>
<li><strong>New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1</strong></li>
<li><strong>Almost one third of surveyed European millennials eligible for routine cervical screening have postponed or skipped their appointment.1</strong></li>
<li><strong>Cervical cancer is one of the most preventable cancers, with almost all cases avoidable through vaccination and regular screenings.2</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>新的研究显示，29-42 岁的人群比其他年龄组更可能错过宫颈筛查。1</strong></li>
<li><strong>几乎三分之一的受访欧洲千禧一代符合常规宫颈筛查资格的人推迟或跳过了他们的预约。1</strong></li>
<li><strong>宫颈癌是最可预防的癌症之一，几乎所有病例都可以通过疫苗接种和定期筛查来避免。2</strong></li>
</ul>
</div><p>, /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today research findings showing that 31% of eligible millennials have postponed or missed their cervical screening appointments – 27% higher than the average across all age groups. The findings come from a survey of 5,518 internet users aged 16-64 commissioned by Roche and conducted by GWI across six European countries.1</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 罗氏（SIX: RO, ROG; OTCQX: RHHBY）今天宣布研究结果显示，31% 的符合条件的千禧一代推迟或错过了他们的宫颈筛查预约，比所有年龄组的平均水平高出 27%。这些发现来自于罗氏委托并由 GWI 在六个欧洲国家进行的对 5,518 名 16-64 岁互联网用户的调查。1</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2339048/Roche_Logo.jpg"/></p>
<p>Despite screening services being widely available free of charge or heavily subsidised in many countries, for the millennials surveyed, specific challenges make accessing routine cervical screening difficult. In addition to the well-documented fears reported over pain, embarrassment or stigma surrounding screenings,1 the research reveals that millennials face a particular challenge in balancing careers, caregiving responsibilities, and relationships. These overlapping commitments appear to push cervical screenings – which remain vital for detecting HPV, the cause of over 99% of cervical cancers3 – to the bottom of their priorities, resulting in higher rates of missed or delayed appointments compared to other groups.</p>
<div class="lb-trans"><p>尽管在许多国家筛查服务广泛免费或大幅补贴，但对于受访的千禧一代而言，特定的挑战使得获取常规宫颈筛查变得困难。除了对疼痛、尴尬或与筛查相关的污名的恐惧外，研究还揭示，千禧一代在平衡职业、照顾责任和人际关系方面面临特别的挑战。这些重叠的承诺似乎将宫颈筛查推到了他们优先事项的底部，导致错过或延迟预约的比例高于其他群体。</p>
</div><p>&#34;Millennials are often said to be the 'have it all generation,' juggling careers,caregiving, and societal expectations. Yet, they tend to put themselves last,&#34; said Joanna Sickler, Vice-President, Health Policy and External Affairs at Roche Diagnostics. &#34;The research shows that millennials are disproportionately failing to prioritise cervical screening, because of a mix of emotional, logistical, and societal pressures. It's critical to design solutions like self-sampling that allow screening to fit into their reality. It's not just important, it's essential to saving lives.&#34;</p>
<div class="lb-trans"><p>&#34;千禧一代常被称为 ‘拥有一切的世代’，在职业、照顾和社会期望之间忙碌。然而，他们往往把自己放在最后，&#34;罗氏诊断的健康政策与外部事务副总裁 Joanna Sickler 表示。&#34;研究显示，千禧一代在优先考虑宫颈筛查方面明显不足，原因是情感、后勤和社会压力的混合。设计像自我采样这样的解决方案，使筛查能够融入他们的现实中至关重要。这不仅重要，更是拯救生命的必要。&#34;</p>
</div><p>The findings highlight the importance of practical, tailored interventions that address the barriers millennials face. Commenting on the results, Professor Daniel Kelly OBE, Cardiff University, and Co-Chair of the HPV and Hep B Action Network at the European Cancer Organisation said: &#34;Healthcare systems must evolve to meet women where and how they live offering flexible, person-centred screening options and access to vaccination while fostering open dialogue and community engagement that normalise cervical health as a shared responsibility.&#34;</p>
<div class="lb-trans"><p>这些发现突显了针对千禧一代面临的障碍的实用、量身定制的干预措施的重要性。评论结果时，卡迪夫大学的 Daniel Kelly OBE 教授及欧洲癌症组织 HPV 和乙型肝炎行动网络的共同主席表示：&#34;医疗系统必须发展，以适应女性的生活方式，提供灵活、以人为本的筛查选项和疫苗接种机会，同时促进开放对话和社区参与，使宫颈健康成为共同责任。&#34;</p>
</div><p>Fear remains the biggest barrier to cervical screening attendance. Thirty percent of all women cite fear as the primary reason for missing or delaying their appointments, driven by anxiety about discomfort, pain, or the potential results. The survey also found that professional commitments and workplace demands are a major factor, and the second-largest barrier for all participants. High-income earners (top third of income ranges across markets) are 22% more likely than average to delay appointments, and 27% of this group cite workplace demands as the reason for postponement. Millennials who delayed or cancelled screening appointments are 20% more likely than the general population to say that greater workplace flexibility and encouragement would help themprioritise cervical screenings.</p>
<div class="lb-trans"><p>恐惧仍然是宫颈筛查出席的最大障碍。30% 的女性将恐惧视为错过或延迟预约的主要原因，主要是由于对不适、疼痛或潜在结果的焦虑。调查还发现，职业承诺和工作场所的要求是一个主要因素，也是所有参与者的第二大障碍。高收入者（市场中收入范围的前 1/3）比平均水平更可能推迟预约，27% 的这一群体将工作场所的要求作为推迟的原因。推迟或取消筛查预约的千禧一代比普通人群更可能（20%）表示，工作场所的灵活性和鼓励会帮助他们优先考虑宫颈筛查。</p>
</div><p>Caregiving responsibilities add another layer of complexity, particularly for parents. For many, the demands of family life take priority over personal health, with 27% of parents surveyed reported they had delayed or cancelled cervical screening appointments.</p>
<div class="lb-trans"><p>照顾责任增加了复杂性，尤其是对于父母而言。对于许多人来说，家庭生活的需求优先于个人健康，27% 的受访父母表示他们推迟或取消了宫颈筛查预约。</p>
</div><p>These challenges are compounded by a lack of awareness and discussion around cervical screening, with half of women surveyed believing there are no schemes to support orsubsidise healthcare appointments. Additionally, nearly 50% of respondents, including 43% of millennials, admitted they had never spoken to anyone about cervical screening, highlighting a pervasive cultural discomfort that leaves many without the emotional support or encouragement needed to prioritise screenings.</p>
<div class="lb-trans"><p>这些挑战因缺乏对宫颈筛查的认识和讨论而加剧，调查中有一半女性认为没有支持或补贴医疗预约的计划。此外，近 50% 的受访者，包括 43% 的千禧一代，承认他们从未与任何人谈论过宫颈筛查，突显出一种普遍的文化不适，使许多人缺乏优先考虑筛查所需的情感支持或鼓励。</p>
</div><p>Practical and emotional support are key to improving attendance rates. Among millennials who postponed their screenings, 12% identified assistance with travel or childcare as a significant motivator, while 19% said greater workplace flexibility and encouragement from employers would help them prioritise their appointments. Emotional support also plays a role, with 10% saying they would be more likely to attend if encouraged by family, friends, or colleagues.</p>
<div class="lb-trans"><p>实用和情感支持是提高出席率的关键。在推迟筛查的千禧一代中，12% 的人认为旅行或儿童照顾的帮助是一个重要的动机，而 19% 的人表示，工作场所的更大灵活性和雇主的鼓励将帮助他们优先考虑预约。情感支持也起着作用，10% 的人表示，如果得到家人、朋友或同事的鼓励，他们更可能参加。</p>
</div><p><strong>Cervical cancer: it only ends with all of us</strong></p>
<div class="lb-trans"><p><strong>宫颈癌：只有我们所有人才能结束</strong></p>
</div><p>Every year, cervical cancer affects more than 600,000 women globally,2 yet it is preventable in almost all cases through vaccination, early detection, and treatment of precancers.2 At Roche Diagnostics, we are committed to the elimination of cervical cancer through collective action. Our campaign, Cervical cancer: it only ends with all of us, focuses on reducing barriers to access, normalising conversations about cervical health, and enabling more eligible individuals to attend their routine screenings.</p>
<div class="lb-trans"><p>每年，宫颈癌在全球影响超过 60 万名女性，2 然而几乎所有病例都可以通过疫苗接种、早期检测和前癌症的治疗来预防。2 在罗氏诊断，我们致力于通过集体行动消除宫颈癌。我们的活动 “宫颈癌：只有我们所有人才能结束” 专注于减少获取障碍，正常化关于宫颈健康的对话，并使更多符合条件的人能够参加常规筛查。</p>
</div><p>Roche is working alongside healthcare systems, governments, and communities to provide flexible screening options such as self-collection, inclusive education, and clear communication about the importance of early detection. Together, we can help improve attendance rates, empower individuals to take action for their health, and prevent cervical cancer from claiming more lives. Eliminating cervical cancer starts with all of us.</p>
<div class="lb-trans"><p>罗氏正在与医疗系统、政府和社区合作，提供灵活的筛查选项，如自我采样、包容性教育和关于早期检测重要性的清晰沟通。我们可以共同帮助提高出席率，赋予个人采取行动保护健康的能力，并防止宫颈癌夺去更多生命。消除宫颈癌始于我们所有人。</p>
</div><p>For more information, visit: https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://roche.com/stories/cervical-cancer-it-only-ends-with-all-of-us</p>
</div><p><strong>About Roche</strong> Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.</p>
<div class="lb-trans"><p><strong>关于罗氏</strong> 罗氏成立于 1896 年，总部位于瑞士巴塞尔，是最早的工业品牌药物制造商之一，现已发展成为全球最大的生物技术公司和体外诊断领域的全球领导者。公司追求科学卓越，致力于发现和开发改善和拯救全球人民生命的药物和诊断工具。我们是个性化医疗的先驱，旨在进一步改变医疗服务的交付方式，以产生更大的影响。为了为每个人提供最佳护理，我们与许多利益相关者合作，将我们的诊断和制药优势与临床实践中的数据洞察相结合。</p>
</div><p>In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.</p>
<div class="lb-trans"><p>罗氏在追求长期视角的努力得到了认可，连续第十五年被道琼斯可持续发展指数评选为制药行业最可持续的公司之一。这一荣誉也反映了我们与每个国家的地方合作伙伴共同改善医疗服务可及性的努力。</p>
</div><p>Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.</p>
<div class="lb-trans"><p>美国的基因泰克是罗氏集团的全资成员。罗氏是日本中外制药的主要股东。</p>
</div><p>For more information, please visit www.roche.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.roche.com。</p>
</div><p>All trademarks used or mentioned in this release are protected by law.</p>
<div class="lb-trans"><p>本发布中使用或提及的所有商标均受法律保护。</p>
</div><p>[1] GWI – Roche. Cervical Cancer Europe Study 2025.</p>
<div class="lb-trans"><p>[1] GWI – 罗氏。2025 年宫颈癌欧洲研究。</p>
</div><p>[2] World Health Organisation. Cervical Cancer Factsheet. Available at URL: https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
<div class="lb-trans"><p>[2] 世界卫生组织。宫颈癌事实表。可在以下网址获取：https://www.who.int/health-topics/cervical-cancer#tab=tab_1</p>
</div><p>[3] Centers for Disease Control, Cancers caused by HPV. Available at URL:https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
<div class="lb-trans"><p>[3] 疾病控制与预防中心，HPV 引起的癌症。可在以下网址获取：https://www.cdc.gov/hpv/about/cancers-caused-by-hpv.html</p>
</div><p><strong>Roche Diagnostics Communications</strong></p>
<div class="lb-trans"><p><strong>罗氏诊断传播</strong></p>
</div><p><strong>Kathryn Ager</strong> Senior Communications Business Partner, Roche Diagnostics</p>
<div class="lb-trans"><p><strong>凯瑟琳·阿格尔</strong> 罗氏诊断高级传播业务合作伙伴</p>
</div><p>kathryn.ager@roche.com</p>
<div class="lb-trans"><p>kathryn.ager@roche.com</p>
</div><p>Phone: +44 07745 115046</p>
<div class="lb-trans"><p>电话：+44 07745 115046</p>
</div><p>SOURCE Roche</p>
<div class="lb-trans"><p>来源：罗氏</p>
</div>

罗氏委托的调查发现，千禧一代是最有可能错过关键宫颈癌筛查的人群 | 罗氏 (ADR) 股票新闻